Chronic Lyme disease is not a single problem. It is a convergence of problems — active pathogen burden, accumulated inflammatory toxins, a dysregulated immune system, and a biological environment so hostile that any intervention applied to it faces significant obstacles from the other problems it hasn't addressed.
This is why single-modality treatment so often fails chronic Lyme patients. Antibiotics target the pathogen but leave the immune dysregulation and inflammatory burden untouched. Immune therapy operates in a system saturated with pro-inflammatory signals that undermine its effects. Anti-inflammatory approaches reduce symptoms temporarily without addressing what's producing them.
The combined protocol at the Lyme Re-code addresses all three dimensions — pathogen burden, inflammatory load, and immune dysregulation — in a coordinated sequence specifically designed so each intervention amplifies the next. The result is a treatment effect that no single modality achieves alone.
To understand why the combined protocol is structured as it is, it helps to understand the three biological problems that need to be addressed simultaneously.
Active pathogen burden — Borrelia and co-infections that continue to drive immune activation, release bacterial antigens, and contribute to tissue inflammation. This is the initial trigger and, in many patients, an ongoing contributor to immune dysregulation even when bacterial load is low.
Accumulated inflammatory burden — pro-inflammatory cytokines, immune complexes, autoantibodies, and bacterial debris that have built up in the bloodstream over months or years of chronic inflammation. These molecules create a toxic internal environment that perpetuates immune overactivation regardless of current pathogen load.
Immune regulatory failure — the progressive depletion and dysfunction of T-Regulatory cells that has left the immune system without the capacity to govern its own responses. This is the mechanism that converts a resolving infection into a chronic, self-sustaining inflammatory condition.
Why addressing only one fails: Treating pathogen load alone leaves the dysregulated immune system and toxic inflammatory environment in place. Treating immune dysregulation alone leaves the pathogen and inflammatory burden to immediately undermine the new regulatory cells. The problems are entangled — they must be addressed together, in the right order.
Therapeutic apheresis comes first because the accumulated inflammatory debris, bacterial fragments, immune complexes, and cytokines in circulation undermine every intervention that follows — and apheresis removes precisely these categories of molecules. What remains is a dramatically reduced inflammatory burden — fewer pro-inflammatory cytokines, fewer immune complexes, a bloodstream significantly less hostile to the immune interventions that follow.
Autologous Treg therapy follows apheresis because it operates most effectively in a clean environment — one where the inflammatory signals that would immediately destabilize newly introduced regulatory cells have been reduced. Reinfusing FOXP3-stabilized Tregs after apheresis has cleared the cytokine burden gives those cells the conditions they need to establish regulatory control. Treg is given in 4 sessions, which spreads out the flu-like reaction many patients feel after an infusion. Together, apheresis and Treg therapy form the 12-day foundation.
In the 18-day program, Heckel whole-body hyperthermia is added after the immune system has been prepared. Borrelia and many co-infections are heat-sensitive, and research suggests a controlled, fever-like state can stress these pathogens, disrupt biofilm communities, and engage the immune system. Applying heat to a cleared, regulated immune system — rather than to an inflamed, dysregulated one — is the reason for this order.
Each intervention in the protocol creates conditions that make the next one more effective. This is not accidental — it is the central rationale for the combined approach.
The Lyme Re-code offers two programs built on one sequence. The 12-Day Program is the standard starting program: autologous Treg cell therapy in 4 sessions, therapeutic apheresis, IV therapy, comprehensive labs and epigenetic testing, nutrition consultation, and daily physician oversight. The 18-Day Program includes everything in the 12-day program plus Heckel whole-body hyperthermia, applied after the immune system has been prepared.
The first days of the program involve baseline evaluation, laboratory assessment, and preparatory IV protocols designed to optimize the patient's physiological state before the major interventions begin. This is not a holding period — it is a deliberate optimization phase that significantly affects the efficacy of what follows.
Apheresis clears the inflammatory environment, and Treg cell collection, processing, stress-test selection, expansion, and reinfusion in 4 sessions restore immune regulation. In the 18-day program, Heckel hyperthermia follows this foundation. It uses water-filtered infrared-A (wIRA) to produce an even, systemic rise in core body temperature; every session is temperature-monitored throughout, and the treatment team adjusts intensity and duration to the individual patient.
Throughout the program, IV therapy protocols — antimicrobials, antioxidants, mitochondrial support, and immune modulators — provide continuous systemic support. Physiotherapy, nutritional guidance, and psychological support address the whole-person dimensions of recovery that purely biomedical treatment cannot.
The combined protocol is designed for patients with significant, longstanding chronic Lyme disease — particularly those who have tried multiple approaches without lasting improvement. It is not appropriate for everyone, and the clinical evaluation prior to program enrollment is thorough.
Whether a patient starts with the 12-day foundation or goes to the 18-day program with Heckel hyperthermia is a medical determination made by the physician after evaluation. Whether hyperthermia is appropriate, and at what intensity, is decided during that evaluation. About two months after the program, the team reassesses and decides whether another round or a different combination is needed.
The decision about which program is appropriate is made individually, based on a comprehensive review of the patient's history, current condition, and treatment goals. No protocol is applied uniformly — every patient receives a program calibrated to their specific biology.
Our clinical team reviews each case individually to determine which program — and which sequence of interventions — best matches your history and goals.
Check My Eligibility